STERIS Q4 2022 Earnings Report
Key Takeaways
STERIS announced strong Q4 2022 results with a 39% increase in revenue to $1.2 billion and adjusted EPS of $2.04. The company anticipates another record year of performance in fiscal year 2023, despite ongoing supply chain and inflation challenges.
Revenue increased by 39% as reported, with an 11% constant currency organic increase.
Reported EPS was $0.52, while adjusted EPS reached $2.04.
Healthcare revenue grew by 32% to $738.8 million.
Applied Sterilization Technologies (AST) revenue increased by 19% to $222.9 million.
STERIS
STERIS
STERIS Revenue by Segment
Forward Guidance
For fiscal year 2023, STERIS anticipates constant currency organic revenue growth of approximately 11% and as reported revenue to increase approximately 12%. Adjusted earnings per diluted share are expected to be in the range of $8.55 to $8.75. Capital expenditures are anticipated to be approximately $330 million and free cash flow is expected to be approximately $675 million.
Positive Outlook
- Constant currency organic revenue growth is anticipated to be approximately 11%.
- As reported revenue is expected to increase approximately 12%.
- Adjusted earnings per diluted share are anticipated to be in the range of $8.55 to $8.75.
- Capital expenditures are anticipated to be approximately $330 million.
- Free cash flow is expected to be approximately $675 million.
Challenges Ahead
- Outlook acknowledges continued supply chain pressure.
- Outlook acknowledges continued inflation pressure.
- Adjusted effective tax rate of 22%.
- Share count of approximately 101 million diluted shares.
- Net impact of acquisitions and divestitures as well as the anticipated negative impact of foreign currency fluctuations.
Revenue & Expenses
Visualization of income flow from segment revenue to net income